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ABSTRACT
One-fourth of individuals diagnosed with the
human immunodeficiency virus concomitantly
have the hepatitis C virus infection. Since the
discovery of highly active antiretroviral
therapy, liver complications have become the
leading cause of morbidity and mortality in
HIV-HCV coinfected individuals. Optimal
treatment in this patient population is critical,
as coinfection has been linked to deterioration
of both disease states. The objective of this
review article is to highlight the current
literature on drug-drug interactions between
HIV and HCV treatments. The management of
the treatment of coinfection patients has been
covered extensively in numerous other
publications.
Keywords: HIV; HCV; HIV–HCV drug
interactions
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INTRODUCTION
Hepatitis C virus (HCV) has emerged as one of
the major worldwide health problems with an
estimated 130–170 million people being
infected [1]. Patients with HCV are
accompanied by chronic liver disease, which
can lead to fibrosis, cirrhosis, and an increased
risk of complications including ascites and
hepatocellular carcinoma. Prior to 2014, the
gold-standard treatment for HCV genotype 1
was a combination of pegylated interferon
(PEG-IFN), including interferon alfa 2a or 2b
and ribavirin (RBV) for a duration of 48 weeks or
longer. However, this treatment has many
limitations including the low sustained
virologic response rate, long duration of
treatment, and difficult adverse event profiles.
The landscape for HCV treatment is dynamic
and rapidly changing. To date, there are four
classes of direct-acting antiviral agents (DAA).
These are NS3/4A protease inhibitors, NS5A
inhibitors, NS5B RNA-dependent polymerase
inhibitors, and non-nucleoside polymerase
inhibitors. Each class differs in their genotype
coverage, treatment status (e.g., treatment-
naı¨ve, relapsers, nonresponders), and
coinfected patient populations.
The development of early DAAs (NS3/4A
protease inhibitors; telaprevir, boceprevir)
instigated a change deviating away from the
previous gold-standard regimen. The two first-
generation NS3/4A protease inhibitors (PI),
telaprevir and boceprevir, were approved in
2011 for the treatment of genotype 1-infected
patients in combination with PEG-IFN and RBV
[2]. Simeprevir, a second-generation NS3/4A PI,
was later approved with the same regimen in
patients with compensated liver disease.
Recently, a nucleotide analog, sofosbuvir,
received FDA approval for the treatment of HCV
genotypes 1–6. Sofosbuvir has completely
changed the basis of the treatment of HCV.
For the first time in the history of this disease, a
non-interferon-based regimen was approved as
first line for the treatment of HCV. Depending
on the hepatitis C genotype, an all-oral regimen
was also made possible. A combination product
consisting of ledipasvir, aNS5A inhibitor, and
sofosbuvir (Harvoni) was the first once-daily
single tablet regimen to treat chronic hepatitis
C genotype 1 and 4 infection in adults. An
additional combination product consisting of
ombitasvir, an NS5A inhibitor, paritaprevir, an
NS3/4A protease inhibitor, dasabuvir, an NS5B
palm polymerase inhibitor, and ritonavir, a
cytochrome P450 3A inhibitor, was also
recently approved.
Highly active antiretroviral therapy (HAART)
is the mainstay therapy for HIV. The standard
recommended treatments for naive patients
with HIV-1 infection usually consist of two
nucleoside/nucleotide reverse transcriptase
inhibitors, in combination with a non-
nucleoside reverse transcriptase inhibitor, a
ritonavir-boosted protease inhibitor, or an
integrase strand transfer inhibitor [3]. Over
recent years, significant advances have been
made to therapy with the introduction of fixed-
dose drug combinations. This allows the
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administration of up to three and more
antiretroviral (ARV) drugs in one tablet,
providing more convenient once-daily
administration such as Atripla, Stribild etc.
[4].
Seven million persons worldwide are
infected with both HIV and HCV [5]. HIV/
HCV coinfection is associated with higher rates
of liver fibrosis, cirrhosis, hepatocellular
carcinoma, and overall mortality compared to
either infection alone [6]. It has been
established that coinfected patients who are
treated optimally for HCV have improved
clinical outcomes and survival [7]. However,
drug interactions among HIV and HCV agents
limit the appropriate treatment of either disease
state, leading to severe complications and even
early deaths in this patient population. This
review is designed to summarize the current
literature on drug interactions between HCV
and HIV treatment regimens.
METHODS
Relevant information was identified through a
comprehensive literature search (January 2003
to March 2015) in PubMed using the keywords
HIV, HCV, HIV/HCV coinfection, non-
structural protein 5B (NS5B) protease
inhibitors, and drug interactions for
boceprevir, dasabuvir, ledipasvir, ombitasvir,
paritaprevir, pegylated interferon, ribavirin,
simeprevir, sofosbuvir and telaprevir. Package
inserts for these drugs were also reviewed.
Abstracts of the articles selected were reviewed,
and those satisfying the inclusion criteria
(pharmacokinetics and drug interactions of
HCV/HIV drugs) were included in the analysis.
Gilead Sciences, Inc., the manufacturer for
Harvoni, was also contacted to confirm its
specific drug interactions with HIV
medications. This content was included in the
review for completeness. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS
This article reviews drug interactions between
established HCV and HIV medications. Drugs
pending approval were not included in this
review because of lack of available data.
Summaries of the drug interactions and their
mechanisms are presented in Tables 1 and 2.
Sofosbuvir (Sovaldi)
Sofosbuvir (SOF) is a direct-acting antiviral
agent against hepatitis C virus infection. It is
an oral nucleotide analog and inhibits NS5B
polymerase, a non-structural protein 5B (NS5B),
and an RNA-dependent RNA polymerase
responsible for the synthesis of copying of the
RNA viral genome [8]. Phase 3 trials of SOF,
involving patients with hepatitis C virus alone,
have demonstrated high rates of sustained
virological response (SVR) when used in
combination with ribavirin for 12 weeks for
hepatitis C virus genotype 2, 12–24 weeks for
HCV genotype 3, and 12 weeks for HCV
genotypes 1, 4, 5, and 6 in combination with
PEG-IFN and RBV [9–11]. Upon oral
administration, SOF is rapidly converted into
the GS-331007 metabolite, which is dominant
and accounts for C90% drug-related exposure in
the body [8]. SOF is responsible only for
approximately 4% drug exposure in the body.
It is a substrate of drug transporter
p-glycoprotein (P-gp) and breast cancer-
resistant protein (BCRP) [8]. However, P-gp
and BCRP do not affect GS-331007, the
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Table 1 Main drug-drug CYP and P-gp interactions between HCV and HIV medications
HCV drug (MOA) Mechanism of
interaction
Drug interaction with HIV drug Effect of drug
interactiona
Sofosbuvir [8] (NS5B
inhibitor)
Substrate for P-gp and
BCRP
Tipranavir/ritonavir (P-gp inducer) ; Sofosbuvir
; GS-331007
(active/dominant
metabolite)
Simeprevir [15] (NS3/4A
protease inhibitor)
Inhibits CYP 3A4
(intestinal), inhibits
P-gp and OATP1B1/3
Substrate for CYP 3A4
Efavirenz
Etravirine
Nevirapine (CYP 3A4 inducers)
; Simeprevir
Cobicistat
Darunavir/ritonavir
Delavirdine
Ritonavir (CYP 3A4 inhibitor)
: Simeprevir
Ritonavir containing products
(atazanavir, fosamprenavir,
lopinavir, indinavir, tipranavir)
(CYP 3A4 inhibitors)
: or ; Simeprevir
Ledipasvir/sofosbuvir [22]
(NS5A inhibitor/NS5B
inhibitor)
Sofosbuvir (see above)
Ledipasvir: Inhibits P-gp
and BCRP
See above See above
Tipranavir/ritonavir (P-gp inducer) ; Ledipasvir
Tenofovir (P-gp substrate) containing
products (efavirenz/emtricitabine/
tenofovir, atazanavir/ritonavir/
emtricitabine/tenofovir, darunavir/
ritonavir/emtricitabine/tenofovir,
lopinavir/ritonavir/emtricitabine/
tenofovir, elvitegravir, cobicistat,
emtricitabine, tenofovir)
: Tenofovir
Boceprevir [26] (NS3/4A
protease inhibitor)
Inhibits P-gp
Inhibits CYP 3A4/5 and
partly CYP 3A4/5
HIV Protease inhibitors: (atazanavir/
ritonavir, darunavir/ritonavir,
lopinavir/ritonavir)
; Boceprevir
; HIV protease
inhibitors
Efavirenz ; Boceprevir
Etravirine ; Etravirine
Rilpivirine : Rilpivirine
Ritonavir (CYP 3A4 inhibitor) ; Boceprevir
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Table 1 continued
HCV drug (MOA) Mechanism of
interaction
Drug interaction with HIV drug Effect of drug
interactiona
Telaprevir [28, 31, 32] (NS3/4A
protease inhibitor)
Strongly inhibits CYP
3A4
Moderately inhibits P-gp
Atazanavir/ritonavir ; Telaprevir
: Atazanavir
Darunavir/ritonavir ; Telaprevir
; Darunavir
Fosamprenavir/ritonavir ; Telaprevir
; Amprenavir
Lopinavir/ritonavir ; Telaprevir
$ Lopinavir
Efavirenz ; Telaprevir
; Efavirenz
Paritaprevir [37] (NS3/4A
protease inhibitor)
Inhibitor of UGT1A1
Metabolized CYP 3A
Inhibitor and substrate of
OATP1B1 and
OATP1B3
Inhibitor of BCRP
Substrate P-gp, BCRP
Atazanavir/ritonavir : Paritaprevir
Darunavir/ritonavir ; Paritaprevir
Darunavir : Paritaprevir
Lopinavir/ritonavir : Paritaprevir
Rilpivirine : Paritaprevir
Ombitasvir [37] (NS5A
inhibitor)
Inhibitor of UGT1A1
Metabolized via amide
hydrolysis CYP plays
minor role
Substrate P-gp and BCRP
Atazanavir/ritonavir ; Ombitasvir
Darunavir/ritonavir ; Ombitasvir
Darunavir ; Ombitasvir
Lopinavir/ritonavir ;: Ombitasvir
Rilpivirine : Ombitasvir
Dasabuvir [37] (non-nucleoside
NS5B palm polymerase
inhibitor)
Inhibitor UGT1A1
Inhibitor BCRP
Metabolized by CYP 2C8
Substrate P-gp and BCRP
Atazanavir/ritonavir ; Dasabuvir
Darunavir/ritonavir ; Dasabuvir
Darunavir ; Dasabuvir
Lopinavir/ritonavir ; Dasabuvir
Rilpivirine : Dasabuvir
Drug interaction for ribavirin and peginterferon was not included in this table because of different drug-interaction
mechanisms
a The direction of the arrow (: = increase, ; = decrease, $ = no change) indicates the direction of the change in drug
concentration
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dominant metabolite [8]. Agents that induce
P-gp in the intestine (e.g., rifampin) may
decrease SOF plasma concentrations, reducing
the therapeutic efficacy of SOF and thereby
increasing the patient’s risk of HCV
exacerbations [8]. On the other hand,
coadministration of SOF with drugs that
inhibit P-gp (e.g., quinidine) and/or BCRP
(e.g., elacridar) may increase the SOF plasma
concentration without increasing the GS-
331007 plasma concentration [8]. Accordingly,
SOF may be coadministered with P-gp and/or
BCRP inhibitors.
Sofosbuvir Drug-Drug Interactions with HIV
Medications
Tipranavir (TPV) is a PI that is indicated for
treatment of resistant HIV genotype-1 infected
patients in combination with other
antiretroviral agents [12]. TPV is a P-gp
inhibitor and therefore may increase the
plasma concentration of SOF, a P-gp substrate.
No studies were found to support this drug
interaction; however, the American Association
for the Study of Liver Diseases (AASLD)
guidelines recommends avoiding the use of
SOF if the patient is concomitantly taking TPV
[13]. The hepatic cytochrome (CYP) P450
enzyme complex does not metabolize SOF [8].
A drug interaction study with efavirenz (EFV),
tenofovir (TDF), emtricitabine (FTC), rilpivirine
(RPV), darunavir/ritonavir (DRV/r), and
raltegravir (RAL) in noninfected individuals
identified no clinically significant interactions
[14]. Since no interactions with cytochrome
P450 enzymes were identified, SOF is an ideal
option for patients with HIV/HCV coinfection.
Simeprevir (Olysio)
Compared to other protease inhibitor
medications, simeprevir (SIM) is a relatively
small macrocyclic drug that targets and
selectively inhibits HCV NS3/4A serine
protease, thereby blocking the enzyme that
enables HCV to replicate in host cells [15]. It is
FDA approved for the treatment of genotype 1
chronic hepatitis C in combination with PEG-
IFN and RBV. SIM is a competitive, reversible,
macrocyclic, noncovalent inhibitor that has
improved affinity and selectivity for protein
targets when compared to telaprevir (TEL) and
BOC [15, 16]. SIM is a weak inhibitor of CYP
1A2 activity and intestinal CYP 3A4 activity,
but does not affect hepatic CYP 3A4 activity.
Furthermore, SIM inhibits OATP1B1/3 and P-gp
transporters. Coadministration of SIM with
drugs that are substrates for CYP 3A4 (e.g.,
amiodarone), OATP1B1/3 (e.g., methotrexate)
and P-gp (e.g., digoxin) transport may result in
increased plasma concentrations of such drugs.
In addition, SIM is also a substrate for CYP 3A4
and can therefore be the subject of drug-drug
interactions with moderate or strong inhibitors
Table 2 Drug-drug interactions for HIV medications when coadministered with Viekira PakTM [37]
HCV DAA Drug interaction with HIV drug Effect of drug interaction AUC
OBV/PTV/r ? DAV Atazanavir/ritonivr : Atazanavir
OBV/PTV/r ? DAV Darunavir : or ; Darunavira
OBV/PTV/r ? DAV Darunavir/ritonavir ; Darunavir
OBV/PTV/r ? DAV Lopinavir/ritonavir ; Lopinavir
OBV/PTV/r ? DAV Rilpivirine : Rilpivirine
a Dependent on dosing regimen
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(e.g., erythromycin) and inducers (e.g., phenytoin)
of CYP 3A4 enzyme, with significant increases
or decreases in exposure to SIM [15].
Simeprevir Drug-Drug Interactions with HIV
Medications
EFV is a non-nucleoside reverse transcriptase
inhibitor (NNRT) and a strong inducer of CYP
3A4 enzyme [17]. Use of SIM with EFV
significantly decreased plasma concentrations
of SIM and therefore their concomitant use is
not recommended [15].
Cobicistat (COBI) is a pharmacokinetics
enhancer with no activity against HIV and is
used with ATZ, DRV, and in a fixed dose
combination of Stribild (elvitegravir/
cobicistat/tenofovir/emtricitabine) [18, 19].
COBI strongly inhibits CYP 3A4 and may
increase SIM plasma concentrations [18]. Use
of SIM with COBI (including COBI-containing
products) is not recommended.
Furthermore, coadministration of SIM and
DRV/r is not recommended because of the
significant increase in SIM exposure (AUC: :
159%’ Cmax: : 79%; Cmin: : 358%) in the
presence of DRV/r, even after dose adjustment
of SIM [15, 20], resulting in their exclusion from
the phase 3 C212 clinical trial assessing
simeprevir in combination with PEG-IFN and
RBV in patients with HIV/HCV coinfection.
Concomitant use of SIM with ritonavir (RTV)
including RTV-containing combinations with
delavirdine (DLV), etravirine (ETR), or
nevirapine (NVP) may result in altered plasma
concentrations of SIM because of CYP 3A4
inhibition (DLV/r) or induction (ETR and
NVP) by these drugs. Coadministration of SIM
with DLV, ETR, NVP, and RTV is not
recommended [15].
The SIM drug interaction study by
Ouwerkerk-Mahadevan et al. [21] found no
substantial interactions with TDF, RPV, and
RAL.
Ledipasvir/Sofosbuvir (Harvoni)
The recently approved Harvoni is a fixed dose
combination of ledipasvir (LDV), an HCV NS5A
inhibitor, and sofosbuvir (SOF), an HCV
nucleotide analog NS5B polymerase inhibitor
[22]. LDV/SOF has been indicated for the
treatment of chronic hepatitis C genotype 1
infection in adults [22]. Efficacy and safety have
been demonstrated in three phase 3 clinical
trials of LDV/SOF administered with or without
RBV [23, 24].
Ledipasvir/Sofosbuvir Drug-Drug Interactions
with HIV Medications
The drug interactions with SOF as discussed
previously apply to this combination as well.
LDV is an inhibitor of the drug transporters P-gp
and BCRP and has the potential to increase
intestinal absorption of coadministered
substrates for these transporters [22]. Two
phase 1, open-label, multiple-dose crossover
PK studies were conducted to evaluate drug-
drug interactions between LDV or LDV/SOF
and common HIV antiretroviral agents in
healthy subjects [25]. LDV or LDV/SOF
pharmacokinetics were unaffected by RAL or a
combination of FTC, RPV, and TDF with brand
name Complera. Small (\20%) changes in RAL
PK were observed with coadministration of LDV
[25]. A modest (*34%) decrease in LDV
exposure was observed with no impact on SOF
PK when coadministered with EFV/FTC/TDF
(Atripla). However, these changes were not
deemed clinically relevant in the study.
Increased TDF exposure was observed when
LDV/SOF was coadministered with EFV/FTC/
TDF (1.98-fold) and FTC/RPV/TDF (1.4-fold)
[22, 25]. It is recommended to consider
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alternative HCV or ARV therapy to avoid an
increase in TDF exposures. If coadministration
is necessary, monitor for TDF-associated adverse
reactions in patients receiving LDV/SOF and
TDF-boosted ARV regimens.
A drug-drug interaction study evaluating
LDV/SOF with Stribild (EVG/COBI/FTC/TDF)
has not been conducted; however, based on its
coadministration with RTV-boosted HIV
protease inhibitors, LDV/SOF with EVG/COBI/
FTC/TDF is expected to increase TDF
concentrations. The safety of increased TDF
concentrations when used in combination with
LDV/SOF and EVG/COBI/FTC/TDF has not been
established. Coadministration of EVG/COBI/
FTC/TDF with LDV/SOF is not recommended
[22].
Coadministration of LDV/SOF with TPV with
RTV is expected to decrease the concentration
of LDV and SOF, leading to a reduced
therapeutic effect of LDV/SOF. According to
prescribing information, coadministration of
LDV/SOF with TPV/RTV is not recommended
[22].
According to the package insert, no clinical
drug interactions have been observed or are
expected when LDV/SOF is used with abacavir
(ABC), ATV/r, DRV/r, EFV, FTC, lamivudine
(3TC), RAL, RPV, or TDF antiretroviral agents
[22].
Boceprevir (Victrelis)
Boceprevir (BOC) is a hepatitis C virus NS3/4A
protease inhibitor and is indicated for the
treatment of chronic hepatitis C genotype 1
infection in adults in combination with PEG-
IFN and RBV [26]. This medication is no longer
recommended for coinfected individuals
because of the lower efficacy rates, longer
treatment duration, substantial drug
interactions, and enhanced adverse effect
profile in comparison to other treatment
alternatives.
Boceprevir Drug-Drug Interactions with HIV
Medications
BOC is primarily metabolized by aldo-
ketoreductase, and this enzyme does not affect
any HIV medication. However, BOC is a strong
inhibitor of CYP 3A4/5 and partly metabolized
by CYP 3A4/5 [26]. Drugs metabolized primarily
by CYP 3A4/5 may have increased exposure
when administered with BOC, which may
increase or prolong their therapeutic and
adverse effects. In addition, BOC is a potential
inhibitor of P-gp based on in vitro studies [26].
A randomized, open-label study assessed the
pharmacokinetic interactions between BOC and
RTV-boosted PIs (PI/r), ATV/r, lopinavir (LPV/r),
or DRV, each with RTV, and concluded that
concomitant administration of BOC with PI/r
reduced exposures of the HIV protease
inhibitors, RTV, and BOC [27]. This study
raises no toxicity-related safety concerns, but
concluded that the drug-drug interactions may
potentially reduce the effectiveness of these HIV
therapies and/or BOC [27]. According to the
prescribing information, plasma trough
concentrations of BOC were decreased when
coadministered with EFV, a strong inducer of
CYP 3A4, and resulted in loss of therapeutic
effect. Therefore, it is not recommended to use
these two agents together [26].
Telaprevir (Incivek)
Telaprevir (TEL) is a direct-acting antiviral agent
against the hepatitis C virus and inhibits HCV
NS3/4A protease, which is essential for viral
replication [28]. TEL is FDA approved for the
treatment of genotype 1 chronic hepatitis C in
adult patients in combination with PEG-IFN
and RBV. It is no longer recommended for
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coinfected individuals because of the lower
efficacy rates, longer treatment duration,
substantial drug interactions, and adverse
effect profile in comparison to other available
treatments.
Telaprevir Drug-Drug Interactions with HIV
Medications
TEL is a strong inhibitor of CYP 3A4 and a
moderate inhibitor of P-gp. Coadministration of
TELwith agents that are primarilymetabolized by
CYP 3A4 (e.g., lovastatin) and/or substrates for
P-gp (e.g., digoxin) transport may result in
increased plasma concentrations of such drugs,
which could increase or prolong their therapeutic
effect and adverse reactions. A pharmacokinetic
study examined the interaction between TEL and
EFV (a known inducer of CYP 3A4), showing that
steady-state EFV decreased the AUC (*26%) and
Cmin (*47%) of telaprevir, whereas TEL had no
significant effects on the PK of EFV [29]. In
another study, TEL increased the exposure of
RPV (*1.8-fold) and decreased the exposures of
DRV/r (*40%) and fosamprenavir/ritonavir
(FPV/r; *47%) [30]. TEL had no effect on RAL,
ATV/r, LPV/r, and/or ETR exposures [31, 32]. On
the other hand, RAL, RPV, ETR, and ATV/r
(*35%), and LPV/r (*54%) significantly
reduced the AUC of TEL [31, 32]. The
prescribing information for TEL does not
recommend its use with DRV/r, FPV/r, and LPV/
r [28]. In addition, according to the prescribing
information, coadministration of TEL and TDF
led to an increase in TDF exposure. Increased
clinical and laboratory monitoring is warranted
in this patient population.
Ribavirin (Rebetol)
Ribavirin (RBV) is a nucleoside analog with
antiviral activity and is indicated for the
treatment of chronic hepatitis C virus
infection in combination with pegylated
interferon alfa 2a or 2b (PEG-IFN) in chronic
hepatitis C patients [33].
Ribavirin Drug-Drug Interactions with HIV
Medications
In vitro studies indicated that RBV does not
inhibit CYP 2C9, CYP 2C19, CYP 2D6, or CYP
3A4, with the least potential for drug
interactions. However, in vitro data results
show that RBV reduces phosphorylation of
3TC, stavudine (D4T), and zidovudine (ZVD)
[33]. Coadministration of RBV and didanosine
(DDI) is contraindicated because of an increased
risk of adverse events, in particular of
mitochondrial toxicity [33]. Based on in vitro
data, RBV increases the intracellular
triphosphate levels of DDI. However, in
another study, pharmacokinetic interactions
were not found between DDI and RBV [34]. In
study NR15961, patients who were
administered ZVD in combination with PEG-
IFN developed severe neutropenia and anemia
more frequently than similar patients not
receiving ZVD (neutropenia 15% vs. 9%)
(anemia 5% vs. 1%) [35]. According to the
prescribing information, it is recommended to
discontinue ZVD as medically necessary.
Pegylated Interferon
(Pegasys, PEG-Intron)
Two pegylated interferon (PEG-IFN a 2a/2b)
molecules are commercially available for the
treatment of chronic hepatitis C. These differ in
the size and nature of the covalently attached
polyethylene glycol (PEG) moiety, with
resulting differences in pharmacokinetics and
dosing regimens [36]; however, these variations
do not affect the overall drug interaction
profile. It is no longer recommended for
coinfected individuals because of the lower
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efficacy rates, longer treatment duration,
substantial drug interactions, and adverse
effect profile in comparison to other available
treatments.
PEG-IFN Drug-Drug Interactions with HIV
Medications
Therapy with PEG-IFN commonly includes
combination therapy with ribavirin. Hence,
the drug interactions described for ribavirin
also apply to the combination of pegylated
interferon and ribavirin. No drug-drug
interactions were found between PEG-IFN and
ARV therapy.
Paritaprevir/Ritonavir/Ombitasvir Plus
Dasabuvir (Viekira PakTM)
The recently approved Viekira PakTM includes a
combination of ombitasvir (OBV), a hepatitis C
NS5A inhibitor, paritaprevir (PTV), a hepatitis C
NS3/4A protease inhibitor, ritonavir (r), a CYP
3A inhibitor, and dasabuvir (DAV), a hepatitis C
non-nucleoside NS5B palm polymerase
inhibitor [37]. OBV/PTV/r ? DAV has been
indicated for the treatment of chronic
hepatitis C genotype 1 infection including
those with compensated cirrhosis. Six phase 3
clinical trials have evaluated the safety and
efficacy of OBV/PTV/r ? DAV with or without
RBV in subjects with chronic hepatitis C
genotype 1 [37–42]. One additional trail
incorporated individuals with HIV/HCV
coinfection [43].
OBV, PTV, and DAV are all inhibitors of
UGT1A1, and RTV is an inhibitor of CYP450
3/A4. PTV is an inhibitor of OATP1B1 and 1B3,
while PTV, RTV, and DAV are inhibitors of
BCRP. Drugs that are substrates may result in
increased plasma concentrations of the drugs
when coadministered with OBV/PTV/r ? DAV
[37]. There is also a potential for other drugs to
alter the effect(s) of one or more of the
components of Viekira PakTM. PTV and RTV
are mainly metabolized by CYP 3A enzymes and
DAV by CYP 2C8 enzymes. Concomitant use of
medications that are inhibitors and/or inducers
of the above enzymes may increase or decrease
the plasma concentrations of these agents. OBV
is primarily metabolized by amide hydrolysis
with only a minor metabolism by CYP enzymes.
OBV, PTV, DAV, and RTV are all substrates of
P-gp. OBV, PTV, and DAV are substrates of
BCRP. PTV is a substrate of OATP1B1 and 1B3.
Many complex drug-drug interactions have the
potential to occur while utilizing OBV/PTV/
r ? DAV. Summaries of the drug interactions
between ARV and DAA are presented in Tables 1
and 2.
Viekira PakTM (PTV/r, OBV, and DAV)
and Drug-Drug Interactions with HIV
Medications
It is recommended to use OBV/PTV/r and DAV
in combination with antiretrovirals that do not
have substantial interactions such as raltegravir
(possibly dolutegravir) enfuvirtide, tenofovir,
emtricitabine, lamivudine, and atazanavir
when possible. If a protease inhibitor is
utilized, it should be given at the same time as
the fixed-dose regimen, and adjustment of the
RTV dose should be considered during the HCV
treatment since the OBV/PTV/r ? DAV contains
RTV as a booster. PTV is metabolized by
cytochrome P450 3A4 (CYP 3A4), and requires
ritonavir boosting to achieve serum levels that
are adequate to treat HCV. Since ritonavir has
anti-HIV activity, HIV/HCV-coinfected patients
should have achieved HIV RNA suppression
prior to initiation of OBV/PTV/r ? DAV. Uses of
this fixed-dose combination should be avoided
because of the potential for low-dose RTV to
select for HIV protease inhibitor resistance in
coinfected patients not recieiving antiretroviral
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therapy. It is not recommended to utilize the
OBV/PTV/r ? DAV combination with efavirenz,
rilpivirine, darunavir, or lopinavir/r combinations
[13].
When OBV/PTV/r ? DAV combination
therapy was combined with efavirenz,
emtricitabine, and tenofovir, clinically
significant gastrointestinal and neurologic
adverse events occurred, with elevations of
alanine aminotransferase levels, thus presenting
a contraindication to coadministration with
efavirenz. When the entire regimen was
combined with rilpivirine, exposure to
rilpivirine was substantially increased. Higher
concentrations of rilpivirine has the potential
to prolong the QT interval; therefore, rilpivirine
should not be used with paritaprevir/ritonavir/
ombitasvir plus dasabuvir and RBV.
Noninfected volunteer studies did not reveal
significant interactions with tenofovir/
emtricitabine or raltegravir that warranted any
dose adjustments or concern for excess toxicity
when utilized together [37]. Since PTV is an
inhibitor of the OATP1B1 bilirubin transporter,
it may increase indirect bilirubin, especially
while taking atazanavir (ATV) as part of the
ARV regimen [44].
PTV has been studied as part of the entire
regimen with boosted HIV protease inhibitors
atazanavir, darunavir, and lopinavir in
noninfected individuals. There were minimal
changes to the maximum concentration (Cmax)
and AUC for these antiretroviral drugs,
although trough concentrations were
increased for atazanavir and lopinavir and
decreased for darunavir. Although paritaprevir
Cmax and AUC values were minimally to
moderately increased, no dose adjustment has
been recommended [45]. Because 100 mg of
ritonavir is coformulated with paritaprevir and
ombitasvir, the total dose of ritonavir must be
carefully considered when using ritonavir-
containing antiretroviral regimens.
Coadministration with ritonavir-boosted
lopinavir would result in 300 mg daily of
ritonavir. This dose has been associated with
adverse gastrointestinal effects; as a result, this
combination is not recommended.
In noninfected volunteers, when OBV/PTV/
r ? DAV was combined with efavirenz,
emtricitabine, and tenofovir, clinically
significant gastrointestinal and neurologic
adverse events occurred [46]. Elevations of
alanine aminotransferase levels occurred when
administered with efavirenz; therefore,
coadministration with efavirenz is not
recommended [46]. When the entire regimen
was combined with rilpivirine, exposures to
rilpivirine were substantially increased [46]. A
higher concentration of rilpivirine has the
potential to prolong the QT interval; therefore,
rilpivirine should not be used with OBV/PTV/r
plus DAV and RBV.
Twenty-eight HIV/HCV-coinfected subjects
already taking ritonavir-boosted atazanavir
(ritonavir coming from the HCV regimen
during the time of coadministration) were
treated with an OBV/PTV/r ? DAV and RBV
regimen as part of the TURQUOISE-1 study
and 35 patients receiving tenofovir/
emtricitabine with raltegravir [43]. Patients
tolerated the combinations well without
requiring discontinuation for treatment-related
serious adverse effects or medication
intolerance.
CONCLUSION
Coinfection with HIV and HCV is a serious
problem resulting in many complications
including faster liver decompensation,
cirrhosis, and hepatic carcinoma. Optimal
treatment is necessary to avoid such
complications. It is very important to address
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drug-drug interactions between these two
regimens to avoid adverse effects and a
decrease in efficacy, thereby increasing
adherence to therapy. Post-marketing data will
be helpful to evaluate and quantify additional
drug interactions/intolerances between HIV and
HCV drugs.
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